Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Dara-KRd for myeloma

Ola Landgren • 10 Apr 2020
Multiple Myeloma Antibodies Carfilzomib Daratumumab Dexamethasone Lenalidomide

Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the use of daratumumab with carfilzomib, lenalidomide, and dexamethasone (dara-KRd) for the treatment of newly diagnosed multiple myeloma. Prof. Landgren goes on to highlight how the achievement of durable responses without the use of transplantation is important in light of the current COVID-19 pandemic that may impact immunosuppressed patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ola Landgren

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
3:51
Should HR-SMM be treated before progression to NDMM?
Ola Landgren • 20 Dec 2023
3:31
ADVANCE: Dara-KRd versus KRd in patients with NDMM
Ola Landgren • 20 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals